Condition: Kaposiform Hemangioendothelioma
Intervention:
Sponsor: Children's Hospital of Fudan University
Recruiting
Feeds
39849 items (39849 unread) in 74 feeds
Acinar Cell Carcinoma
(940 unread)
Acinic Cell Carcinoma
(353 unread)
Adenoid Cystic Carcinoma
(508 unread)
Adrenal Gland Cancer
(3445 unread)
Ampulla Of Vater
(571 unread)
Anal Cancer
(3170 unread)
Angiosarcoma
(999 unread)
Appendix Cancer
(1255 unread)
Bile Duct Cancer
(5367 unread)
Brain and CNS
(7637 unread)
Carcinoid
(844 unread)
Endocrine/Neuroendocrine
(6579 unread)
Gall Bladder Cancer
(1794 unread)
Hemangioendothelioma
(1742 unread)
Hepatoblastoma
(540 unread)
Pancreas
(596 unread)
Phyllodes
(486 unread)
PMP and Mucinous Tumors
(395 unread)
Rhabdomyosarcoma
(1272 unread)
Sarcoma
(1356 unread)
Trial - Hemangioendothelioma (10 unread)
-
The Effect of Sirolimus on Immunizations During the Treatment of Kaposiform Hemangioendothelioma
Posted: April 28th, 2022, 2:00pm GMT
-
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors
Posted: February 8th, 2022, 3:00pm GMT
Conditions: Solid Tumors, Adult; Solid Tumor; Mesothelioma (MPM); Epithelioid Hemangioendothelioma (EHE); NF2 Deficient Mesothelioma; Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes; NF2 Deficiency; YAP1 or TAZ Gene Fusions
Intervention: Drug: IK-930
Sponsor: Ikena Oncology
Recruiting -
Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma
Posted: March 5th, 2021, 3:00pm GMT
Conditions: Advanced Sarcoma
Interventions: Drug: Lenvatinib; Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center; Merck Sharp & Dohme LLC; Parker Institute for Cancer Immunotherapy
Recruiting -
Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.
Posted: March 1st, 2021, 3:00am GMT
Conditions: Kaposiform Hemangioendothelioma
Interventions: Drug: Sirolimus
Sponsors: West China Hospital
Completed -
Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group
Posted: May 30th, 2019, 2:00pm GMT
Conditions: Soft Tissue Sarcoma; Clear Cell Sarcoma; Epithelioid Sarcoma; Perivascular Epithelioid Cell Neoplasms; Desmoplastic Small Round Cell Tumor; Malignant Solitary Fibrous Tumors; Alveolar Soft Part Sarcoma; Epithelioid Hemangioendothelioma; Low Grade Fibromyxoid Sarcoma; Sclerosing Epithelioid Fibrosarcoma
Interventions: Other: Patient with Soft Tissue Sarcoma
Sponsors: Institut Claudius Regaud
Recruiting -
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Posted: September 11th, 2017, 2:00pm GMT
Conditions: Soft Tissue Sarcoma; Bone Sarcoma
Interventions: Drug: Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]; Drug: Nivolumab 100 MG/10 ML [Opdivo]; Drug: Epirubicin; Drug: Ifosfamide; Drug: Doxorubicin; Drug: Dacarbazine; Drug: Cisplatin; Drug: Methotrexate
Sponsor: Grupo Espanol de Investigacion en Sarcomas
Recruiting -
Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery
Posted: May 10th, 2017, 2:00am GMT
Conditions: Locally Advanced Epithelioid Hemangioendothelioma; Metastatic Epithelioid Hemangioendothelioma; Unresectable Epithelioid Hemangioendothelioma
Interventions: Other: Questionnaire Administration; Drug: Trametinib
Sponsors: National Cancer Institute (NCI)
Completed -
Identification of Biomarkers for Patients With Vascular Anomalies
Posted: December 22nd, 2016, 3:00pm GMT
Conditions: Vascular Anomaly; Generalized Lymphatic Anomaly; Kaposiform Hemangioendothelioma; Kaposiform Lymphangiomatosis; Gorham-Stout Disease; Klippel Trenaunay Syndrome; Congenital Lipomatous Overgrowth, Vascular Malformations, and Epidermal Nevi
Intervention:
Sponsors: Children's Hospital Medical Center, Cincinnati; Lymphangiomatosis and Gorham's Disease Alliance (LGDA); Klippel Trenaunay (KT) Support Group; CLOVES Syndrome Community Support Group
Recruiting -
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
Posted: June 28th, 2016, 2:00am GMT
Conditions: Advanced and/or Metastatic Sarcoma
Interventions: Drug: Durvalumab; Drug: Tremelimumab
Sponsors: M.D. Anderson Cancer Center; MedImmune LLC
Active, not recruiting -
A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors
Posted: April 10th, 2014, 2:00am GMT
Conditions: Kaposiform Hemangioendothelioma (KHE); Kasabach-Merritt Syndrome; Tufted Angioma
Interventions: Drug: Vincristine; Drug: Sirolimus
Sponsors: Boston Children's Hospital; Pfizer
Terminated